Ten Things You Should Know About Nanotechnology

Every technology carries some risk, and nanotechnology is no exception. The key question is not whether nanomaterials pose any risk at all, but whether specific nanomaterials in specific applications pose risks that outweigh their benefits, and whether those risks can be understood and managed.

The mere presence of nanomaterials is not inherently dangerous. Nanoparticles exist naturally in the environment, from volcanic ash to sea spray to forest fire smoke. Humans have been exposed to engineered nanoparticles for over a century through products like carbon black in tires and rubber goods. What matters are the specific properties of specific materials: their size, shape, surface chemistry, solubility, and how they interact with biological systems.

It is worth noting that billions of doses of COVID-19 mRNA vaccines, which rely on lipid nanoparticles for delivery, have been safely administered worldwide. Meanwhile, numerous nanomedicines have received regulatory approval after demonstrating acceptable safety profiles in clinical trials. This demonstrates that nanomaterials can be used safely when properly designed and tested.

Nanotoxicology, the study of potential toxic effects of nanomaterials, has matured significantly over the past two decades. Researchers have developed a much better understanding of how nanoparticle properties influence biological interactions.

Because nanoparticles behave differently from bulk materials of the same composition, the toxicity of a nanomaterial cannot simply be predicted from the known toxicity of the bulk material. A substance that is harmless in bulk form might be reactive at the nanoscale, or vice versa. This requires nanomaterial-specific safety testing.

One important distinction is between "fixed" and "free" nanoparticles. Nanoparticles embedded in a solid matrix, such as carbon nanotubes in a composite material, generally pose less concern than free nanoparticles that can be inhaled, ingested, or absorbed through skin. Most safety concerns focus on exposure to free nanoparticles during manufacturing, use, or disposal.

Nanoparticles can enter the body through four main routes: inhalation, ingestion, skin absorption, and injection (in medical applications). Once inside the body, their small size allows them to travel to places larger particles cannot reach, and in some cases to cross biological barriers including the blood-brain barrier.

The biological effects of nanoparticles depend on where they go and how long they stay there. Some nanoparticles are rapidly cleared by the body's normal elimination processes. Others may persist in tissues or accumulate in organs. The large surface area of nanoparticles means they can interact with proteins, cell membranes, and DNA in ways that larger particles of the same material would not.

Potential concerns include inflammation from nanoparticles that accumulate in the lungs, oxidative stress from reactive nanoparticle surfaces, and interference with cellular processes. However, many of these effects depend strongly on the specific nanomaterial, dose, and exposure route. Read more about nanoparticles, free radicals, and oxidative stress.

Environmental concerns focus on what happens when nanomaterials are released into air, water, or soil, whether during manufacturing, product use, or disposal. Questions include: How do nanoparticles move through the environment? Do they persist or degrade? Do they accumulate in organisms or ecosystems? Can they affect microbial communities that perform essential ecological functions?

A related and increasingly prominent concern is micro and nanoplastics. These are not engineered nanomaterials but rather the breakdown products of plastic waste. Nanoplastics have been detected in water, food, air, and human tissues. Research into their health effects is ongoing, but they represent a significant environmental and potentially health concern distinct from intentionally manufactured nanomaterials.

Assessing environmental risks requires understanding the full lifecycle of nanomaterials: fabrication, incorporation into products, product use, and eventual disposal or recycling. Different stages may present different exposure scenarios and risks.

Unlike the early days of nanotechnology when regulatory frameworks were largely absent, comprehensive rules now govern nanomaterials in major markets. These regulations require manufacturers to assess and document the safety of nanomaterials before placing them on the market.

In the European Union, nanomaterials are regulated under the REACH regulation (Registration, Evaluation, Authorisation and Restriction of Chemicals). Since 2020, companies manufacturing or importing nanomaterials in quantities of one tonne or more per year must submit dedicated registration dossiers to the European Chemicals Agency (ECHA), including specific characterization of nanoforms. Additional sector-specific regulations cover nanomaterials in cosmetics, food, biocides, and medical devices. Several EU member states, including France, Belgium, and Denmark, also maintain national nanomaterial registries.

In the United States, the Environmental Protection Agency (EPA) regulates nanomaterials under the Toxic Substances Control Act (TSCA). A 2017 rule requires reporting and recordkeeping for certain nanomaterials. The FDA provides guidance on nanotechnology in food, cosmetics, and medical products. Other agencies address nanomaterials within their respective domains.

International coordination continues through organizations like the OECD Working Party on Manufactured Nanomaterials, which has developed testing guidelines and safety assessment frameworks that inform regulations worldwide.

Rather than treating safety as an afterthought, the "safe-by-design" approach integrates safety considerations from the earliest stages of nanomaterial development. This means considering potential hazards when selecting materials, designing particles with properties that minimize risk (such as coatings that reduce reactivity or promote biodegradation), and engineering products to minimize exposure throughout their lifecycle.

This approach recognizes that it is more efficient to design safety into nanomaterials from the beginning than to discover problems after significant investment in development and commercialization. It also reflects a broader commitment to responsible innovation, where potential risks and societal implications are considered alongside technical performance and commercial potential.

Discussions of nanotechnology risk often invoke the precautionary principle: the idea that if an action might cause serious harm, protective measures should be taken even in the absence of complete scientific certainty. The EU has generally embraced this principle in its regulatory approach, while the US has tended toward a more risk-benefit framework.

Critics of strict precautionary approaches argue that they can stifle innovation and delay beneficial applications. Advocates counter that the long history of technologies whose risks were recognized only after widespread deployment, from asbestos to certain pesticides, justifies caution with novel materials whose long-term effects may not yet be fully understood. (See: "Late lessons from early warnings for nanotechnology")

In practice, most regulatory systems try to balance these perspectives: requiring safety evidence before commercialization while not demanding impossible proof of zero risk. The goal is to enable beneficial applications while protecting public health and the environment.

The nanotechnology safety landscape has evolved considerably. We have moved from a period of limited knowledge and regulatory uncertainty to one with established research methods, comprehensive regulations, and growing databases of safety information. This does not mean all questions are answered, but it does mean there are frameworks for asking and answering them.

Ongoing challenges include keeping regulations updated as new types of nanomaterials emerge, developing standardized testing methods that can efficiently assess the many variations of nanomaterials, and understanding long-term effects that may only become apparent after years of exposure. The scientific community, regulators, and industry continue to work on these challenges.

With an understanding of the risk landscape, we can turn to the broader societal aspects of nanotechnology.